The Parkinson’s Academy draws on a team of expert professionals with a rich blend of skills in treating and managing patients with Parkinson’s. Many of our speakers have a background in both clinical and research work, and so bring to bear both their practical experience as well as their knowledge about the evidence base for […]
The team at Parkinson’s UK know just how important it is that people living with Parkinson’s are cared for by professionals that understand their condition and for that reason is education for professionals is a top priority.
The course will advance understanding of Parkinson’s disease and related movement disorders through taught sessions and mentorship (a mentor will be appointed for each participant). This course will been awarded external CPD credits by the Federation of the Royal Colleges of Physicians.
Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease.
In general terms patients with Parkinson’s disease are able to drive as long as they are physically and psychologically in a fit state so to do. We all take personal responsibility only to drive when we are able to – this applies to people with Parkinson’s in the same way as it does to the […]
In this edition of the Parkinson’s Academy MasterClass in-house journal, now renamed 'MasterClass: Moving On', Doug MacMahon appropriately reflects on the last 12+ years and how we have gone from nothing to where we are now. Masterclasses 27 and 28 beckon in 2015...